Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
74 studies found for:    "Wegener granulomatosis"
Show Display Options
Rank Status Study
21 Recruiting Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis;   Wegener's
Intervention:
22 Recruiting Determining Disease Activity Biomarkers in Individuals With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
Conditions: Eosinophilic Granulomatosis With Polyangiitis;   Churg-Strauss Syndrome
Intervention:
23 Recruiting Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)
Conditions: Granulomatosis With Polyangiitis (Wegener's);   Granulomatosis With Polyangiitis;   Wegener's Granulomatosis;   ANCA-Associated Vasculitis
Interventions: Drug: Abatacept;   Drug: placebo
24 Unknown  Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)
Conditions: Wegener's Granulomatosis;   Vasculitis
Interventions: Drug: mycophenolate mofetil;   Drug: cyclophosphamide
25 Unknown  WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides
Condition: Systemic Wegener's Granulomatosis
Interventions: Drug: Azathioprine: 2 mg/kg/day;   Drug: methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
26 Completed
Has Results
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Conditions: Vasculitis;   Wegener's Granulomatosis;   Microscopic Polyangiitis
Interventions: Drug: Rituximab plus cyclophosphamide placebo (rituximab group);   Drug: Cyclophosphamide plus rituximab placebo (control group);   Drug: Azathioprine;   Drug: Methylprednisolone (or other glucocorticoid);   Drug: Prednisone
27 Recruiting The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach
Condition: Granulomatosis With Polyangiitis
Interventions: Drug: Prednisone 5 mg/day;   Drug: Prednisone 0 mg/day
28 Completed Efficacy Study of Two Treatments in the Remission of Vasculitis
Conditions: Wegener's Granulomatosis,;   Microscopic Polyangiitis
Interventions: Drug: Rituximab;   Drug: Azathioprine
29 Terminated Plasma Exchange for Renal Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis
Interventions: Procedure: Plasma exchange;   Drug: Intravenous methyl prednisolone;   Drug: Methyl prednisolone
30 Recruiting The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
Conditions: Granulomatosis With Polyangiitis;   Wegener Granulomatosis;   Vasculitis
Interventions: Drug: 5 mg prednisone;   Drug: 0 mg prednisone
31 Completed A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
Condition: Churg-Strauss Syndrome
Interventions: Biological: Mepolizumab;   Drug: Placebo
32 Not yet recruiting Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Condition: Asthma
Intervention: Drug: Reslizumab
33 Withdrawn BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Interventions: Drug: Blisibimod;   Drug: Placebo
34 Completed Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)
Conditions: MPA;   PAN or EGPA With FFS=0;   At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids
Interventions: Drug: corticosteroid and azathioprine;   Drug: corticosteroid and placebo
35 Active, not recruiting PRO Development for ANCA Associated Vasculitis
Conditions: Wegener Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome
Intervention:
36 Completed Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
Conditions: ANCA Associated Systemic Vasculitis;   Wegener's Granulomatosis;   Microscopic Polyangiitis
Intervention: Drug: cyclophosphamide
37 Completed Anti-Cytokine Therapy for Vasculitis
Conditions: Wegener's Granulomatosis;   Renal Limited Vasculitis;   Microscopic Polyangiitis
Interventions: Biological: Infliximab;   Drug: Cyclophosphamide;   Drug: Prednisolone;   Drug: Azathioprine;   Procedure: Plasma exchange;   Drug: Mycophenolate mofetil;   Drug: Methylprednisolone
38 Active, not recruiting Rituximab Vasculitis Maintenance Study
Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;   Microscopic Polyangiitis;   Wegener Granulomatosis
Interventions: Biological: Rituximab;   Drug: Azathioprine
39 Completed Steroids and Methotrexate to Treat Systemic Vasculitis
Conditions: Inflammation;   Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: prednisone and methotrexate
40 Active, not recruiting Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
Conditions: Granulomatosis With Polyangiitis (Wegener's) (GPA);   Microscopic Polyangiitis (MPA)
Interventions: Procedure: Plasma Exchange;   Drug: Glucocorticoids

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.